Related Experiment Video
Updated: Feb 8, 2026

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
Published on: May 24, 2016
CD73 expression and clinical significance in human metastatic melanoma
Inês Monteiro1, Selena Vigano2, Mohamed Faouzi3
1Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
Background:
CD73 is an ectoenzyme involved in the production of adenosine. It exerts immunosuppressive and protumoral roles and has emerged as a potential immuno-oncology target.
Results:
CD73 expression was detected in TC in 54% of melanoma metastases, involving < 50% TC in the majority of the cases, with variable intensity. CD73 expression was significantly associated with a lower Breslow's depth of the primary lesion and was more frequent in patients having received prior non-surgical therapies. In an adjusted analysis, CD73 expression in TC (H-score > 37.5 or intensity > 1) significantly correlated to decreased overall survival (OS) from biopsy. Of the samples containing TIMC, 35% presented CD73+ TIMC. Highly infiltrated tumors were more likely to contain CD73+ TIMC. CD73 expression in TIMC (percentage ≥1%) significantly correlated with improved OS from biopsy.
Conclusions:
Immunohistochemistry detected CD73 expression in more than half of metastatic melanomas. While CD73 expression in TC significantly correlated with decreased OS, CD73 expression in TIMC significantly associated with improved OS. These results encourage the study of anti-CD73 therapies for metastatic melanoma patients.
Methods:
CD73 expression was assessed by immunohistochemistry in metastatic melanomas from 114 patients. Immunostainings were evaluated in tumor cells (TC) (percentage, intensity (1-3) and H-score) and in tumor-infiltrating mononuclear cells (TIMC) (percentage).
Insights
CD73 expression in tumor cells correlates with worse survival in melanoma, but CD73 in immune cells suggests better outcomes. These findings support exploring anti-CD73 therapies for metastatic melanoma.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- CD73 is an ectoenzyme that produces adenosine.
- It plays roles in immune suppression and tumor growth.
- CD73 is a potential target for immuno-oncology therapies.
Purpose of the Study:
- To investigate CD73 expression in metastatic melanoma.
- To determine the association between CD73 expression and patient survival.
Main Methods:
- Immunohistochemistry was used to assess CD73 expression in 114 metastatic melanoma patients.
- Evaluated CD73 in tumor cells (TC) and tumor-infiltrating mononuclear cells (TIMC).
Main Results:
- CD73 was detected in 54% of metastatic melanomas.
- CD73 in TC correlated with decreased overall survival (OS).
- CD73 in TIMC correlated with improved OS.
Conclusions:
- CD73 expression has opposing prognostic roles in melanoma based on its location (TC vs. TIMC).
- Results support further investigation of anti-CD73 therapies for metastatic melanoma.
Related Concept Videos
Statistical Significance
Significance of Center of Mass
The Significance of Membrane Transport
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Significance Testing: Overview
Significance of Displacement Current

